Gilead Says Findings Positive From Real-World Use of Yescarta in Lymphoma
December 09 2019 - 3:43PM
Dow Jones News
By Michael Dabaie
Gilead Sciences Inc. (GILD) said its Kite subsidiary had
positive findings from real-world use of Yescarta in relapsed or
refractory large B-Cell lymphoma.
Kite and the Center for International Blood and Marrow
Transplant Research unveiled the findings from an ongoing
post-marketing study evaluating the safety and efficacy of Yescarta
in adult patients.
In the analysis, efficacy and safety of Yescarta were comparable
to that observed in the ZUMA-1 trial, despite a larger proportion
of older, more difficult-to-treat patients in the real-world
setting, Gilead said.
Yescarta was approved by the U.S. Food and Drug Administration
in 2017 for the treatment of adult patients with relapsed or
refractory large B-cell lymphoma.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 09, 2019 15:28 ET (20:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024
